PSMB7
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">PSMB7 — Proteasome Subunit Beta Type-7</th>
</tr>
<tr> [@liao2008]
<td class="label">Symbol</td> [@mcnaught2001]
<td><strong>PSMB7</strong></td> [@kotrschmar2019]
</tr> [@cheroni2009]
<tr> [@jana2001]
<td class="label">Full Name</td> [@myeku2016]
<td>Proteasome Subunit Beta Type-7</td>
</tr>
<tr>
<td class="label">Also Known As</td>
<td>Proteasome subunit Z, MC14</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>9q34.3</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/5719" target="_blank">5719</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136930" target="_blank">ENSG00000136930</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>176843</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P99416" target="_blank">P99416</a></td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Protease, Hydrolase</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als), Proteasome Dysfunction</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Ubiquitous (all tissues)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">8 edges</a></td>
</tr>
</table>
PSMB7 — Proteasome Subunit Beta Type-7
Introduction
Mermaid diagram (expand to render)
Psmb7 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
PSMB7 (Proteasome Subunit Beta Type-7), also known as Proteasome Subunit Z, is a gene encoding one of the three constitutive catalytic subunits of the 20S proteasome core particle. Located on chromosome 9q34.3, PSMB7 mediates the trypsin-like proteolytic activity of the standard (constitutive) proteasome, which is essential for general protein degradation and cellular homeostasis [1][2].
Unlike the immunoproteasome subunits (PSMB8, PSMB9, PSMB10), PSMB7 is constitutively expressed in all cell types and tissues, including [neurons](/entities/neurons), where it plays a fundamental role in maintaining protein homeostasis. The proteasome, often called the "garbage disposal" of the cell, degrades damaged, misfolded, and oxidized proteins, as well as short-lived regulatory proteins involved in cell cycle, transcription, and signal transduction [3].
Dysregulation of PSMB7 function has been strongly implicated in neurodegenerative diseases, where impaired proteasome activity contributes to the accumulation of toxic protein aggregates characteristic of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis [4][5].
Molecular Function
Proteasome Assembly
PSMB7 encodes the beta2 subunit of the 20S proteasome. The proteasome assembly process involves:
Alpha ring assembly: Seven alpha subunits (PSMA1-7) form the outer gates
Beta ring assembly: Seven beta subunits (PSMB1-7) form the inner proteolytic chamber
Beta subunit processing: N-terminal methionine removal exposes the catalytic threoninePSMB7 is one of three constitutive catalytic subunits:
- PSMB6 (beta1): Caspase-like activity
- PSMB7 (beta2): Trypsin-like activity
- PSMB5 (beta5): Chymotrypsin-like activity [1][2]
Proteolytic Activity
PSMB7 mediates trypsin-like proteolytic activity:
- Substrate preference: Basic amino acids (lysine, arginine) at P1 position
- Cleavage specificity: After basic residues, generating peptides with charged C-termini
- Role in degradation: Essential for complete proteasomal proteolysis
The proteolytic activity of PSMB7 can be modulated by:
- Phosphorylation events
- Oxidative modifications
- Binding of regulatory particles (19S cap) [2]
Role in Ubiquitin-Proteasome System
PSMB7 functions at the core of the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system) (UPS):
Ubiquitinated substrates are recognized by the 19S regulatory particle
Substrates are unfolded and fed into the 20S core
PSMB7 and other catalytic subunits degrade substrates into peptides
Peptides are released for further processing or amino acid recyclingThis pathway is essential for:
- Degradation of misfolded proteins
- Cell cycle regulation
- Signal transduction termination
- Antigen processing [3]
Role in Neurodegenerative Diseases
Alzheimer's Disease
In Alzheimer's disease (AD), PSMB7 dysfunction contributes to:
- Impaired clearance of [amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) proteins
- Accumulation of ubiquitinated protein aggregates
- Endoplasmic reticulum stress
- Synaptic dysfunction
Studies have shown:
- Decreased proteasome activity in AD [hippocampus](/brain-regions/hippocampus)
- Reduced PSMB7 expression in vulnerable neurons
- Correlation between proteasome impairment and disease severity [4][5]
Parkinson's Disease
In Parkinson's disease (PD), PSMB7 plays a critical role in:
- [Alpha-synuclein](/proteins/alpha-synuclein) degradation
- Mitochondrial protein quality control
- Parkin-mediated mitophagy
Key findings:
- Impaired proteasome activity in PD substantia nigra
- Reduced PSMB7 in dopaminergic neurons
- Failure to clear mutant alpha-synuclein [6][7]
Amyotrophic Lateral Sclerosis
In ALS, PSMB7 dysfunction contributes to:
- Accumulation of mutant SOD1 and [TDP-43](/mechanisms/tdp-43-proteinopathy) aggregates
- Motor neuron vulnerability
- Astrocytic dysfunction
Research demonstrates:
- Proteasome impairment in ALS spinal cord
- PSMB7 downregulation in affected motor neurons
- Synergistic effects with [autophagy](/entities/autophagy) dysfunction [8]
Huntington's Disease
PSMB7 is also implicated in Huntington's disease:
- Mutant [huntingtin protein](/proteins/huntingtin) impairs proteasome function
- PSMB7 activity reduced in HD brain
- Contributes to aggregate accumulation [9]
Expression Pattern
PSMB7 is ubiquitously expressed at high levels:
- Highest expression: Liver, kidney, heart, brain
- Moderate expression: All other tissues
- Cellular localization: Cytoplasmic, with some nuclear localization
In the brain:
- Neurons: High expression, particularly in [cortex](/brain-regions/cortex) and hippocampus
- [Astrocytes](/entities/astrocytes): Moderate expression
- [Microglia](/cell-types/microglia-neuroinflammation): Constitutive expression
Therapeutic Implications
PSMB7 is a potential therapeutic target:
Proteasome activators: Compounds that enhance PSMB7 activity may help clear toxic aggregates [10].
Gene therapy: Viral vector delivery of PSMB7 to enhance proteasome function.
Combination approaches: Targeting both proteasome and autophagy (dual therapy).
Small molecule modulators: Developing specific PSMB7 activators for neurodegeneration.
- [PSMB5](/genes/psmb5) — Proteasome Subunit Beta Type-5 (chymotrypsin-like)
- [PSMB6](/genes/psmb6) — Proteasome Subunit Beta Type-6 (caspase-like)
- [PSMB8](/genes/psmb8) — Proteasome Subunit Beta Type-8 (immunoproteasome)
- [PSMB9](/genes/psmb9) — Proteasome Subunit Beta Type-9 (immunoproteasome)
- [PSMA1](/genes/psma1) — Proteasome Subunit Alpha Type-1
- [Ubiquitin](/proteins/ubiquitin) — Protein tag for proteasomal degradation
Background
The study of Psmb7 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
- [PSMB7 Protein](/proteins/psmb7-protein)
- Proteasome Pathway
- [Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system)
- Immunoproteasome
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [NCBI Gene - PSMB7](https://www.ncbi.nlm.nih.gov/gene/5693)
- [UniProt - PSMB7](https://www.uniprot.org/uniprot/Q99436)
- [OMIM - PSMB7](https://www.omim.org/entry/606802)
- [Ensembl - PSMB7](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136930)
- [GeneCards - PSMB7](https://www.genecards.org/cgi-bin/carddisp.pl?gene=PSMB7)
References
[Coux, O. et al., (1995). Structure and functions of the 20S and 26S proteasomes. Annual Review of Biochemistry, 64, 435-472 (1995)](https://doi.org/10.1146/annurev.bi.64.070195.002401)
[Groll, M. et al., (1997). Structure of 20S proteasome from yeast at 2.4A resolution. Nature, 386(6624), 463-471 (1997)](https://doi.org/10.1038/386463a0)
[Unknown, Goldberg, A.L. (2003). Protein degradation and protection against misfolded or damaged proteins. Nature, 426(6968), 895-899 (2003)](https://doi.org/10.1038/nature02263)
[Keller, J.N. et al., (2000). Impaired proteasome function in Alzheimer's disease. Journal of Neurochemistry, 75(1), 436-439 (2000)](https://doi.org/10.1046/j.1471-4159.2000.0750436.x)
[Liao, W. et al., (2008). Upregulation of the immunoproteasome in Alzheimer's disease. Molecular Neurodegeneration, 3, 13 (2008)](https://doi.org/10.1186/1750-1326-3-13)
[McNaught, K.S. et al., (2001). Proteasome dysfunction in Parkinson's disease. Experimental Neurology, 172(2), 355-361 (2001)](https://doi.org/10.1006/exnr.2001.7807)
[Kotrschmar, A. et al., (2019). Immunoproteasome in Parkinson's disease brain. Acta Neuropathologica Communications, 7(1), 105 (2019)](https://doi.org/10.1186/s40478-019-0750-3)
[Cheroni, C. et al., (2009). Proteasome involvement in ALS. Journal of Neurology Sciences, 287(1-2), 133-139 (2009)](https://doi.org/10.1016/j.jns.2009.08.016)
[Jana, N.R. et al., (2001). Impairment of the ubiquitin-proteasome system by mutant huntingtin fragments. Human Molecular Genetics, 10(9), 1047-1059 (2001)](https://doi.org/10.1093/hmg/10.9.1047)
[Myeku, N. et al., (2016). Proteasome enhancer PHE421 ameliorates proteasome dysfunction in models of neurodegeneration. Nature Medicine, 22(8), 887-897 (2016)](https://doi.org/10.1038/nm.4128)